Exhaled Breath Particles as a Clinical Indicator for Lung Injury and Acute Respiratory Distress Syndrome (ARDS)

Sponsor
Lund University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04503057
Collaborator
(none)
300
1
60
5

Study Details

Study Description

Brief Summary

Acute Respiratory Distress Syndrome (ARDS) reflects the hallmark of the critical course of coronavirus (COVID19). The investigators have recently shown that Exhaled Breath Particles (EBP) measured as particle flow rate (PFR) from the airways could be used as a noninvasive real-time early detection method for primary graft dysfunction (which bears a pathophysiological resemblance to ARDS) in lung transplant patients. The investigators have also previously demonstrated the utility of PFR in early detection and monitoring of ARDS in a large animal model. PFR has been shown to be elevated prior to the cytokine storm which classically occurs in ARDS. Early detection of ALI and ARDS is intimately linked to a patient's chance of survival as early treatment consisting of the preparation for intensive care, prone positioning and protective mechanical ventilation can be implemented early in the process. In the present study the investigators aim to use real-time PFR as an early detector for COVID19-induced ARDS. The investigators will also collect EBPs onto a membrane for subsequent molecular analysis. Previous studies have shown that most of those proteins found in bronchoalveolar lavage (BAL) can also be detected in EBPs deposited on membranes. The investigators therefore also aim to be able to diagnose COVID19 by analyzing EBPs using Polymerase Chain Reaction (PCR) with the same specificity as PCR from BAL, with the added benefit of being able to identify protein biomarkers for early detection of ARDS.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    EBP will be measured on 100 patients who are coronavirus (COVID-19) positive as indicated by PCR tests. Measurement will be done on daily basis from the time the patient is admitted to the hospital as an inpatient until either discharge or transition to ICU care. The initiation of mechanical ventilation in ICU patients will facilitate the tracking of EBP patterns over the course of disease in each patient. EBP measurements will also be done on 100 patients without COVID19 infection who have normal lung function as a control cohort.

    The study will involve measurements on patients who have been placed on mechanical ventilation in the ICU. The purpose of utilizing PFR will be to reduce the need for invasive diagnostic tests such as bronchoscopy and for hospital transportation associated with tests such as CT scans. This will ultimately serve to not only decrease the risk of infecting other patients and staff in the hospital environment, but also to facilitate careful monitoring of these critical patients by measuring the extent of lung injury over time. In addition to PFR, EBP will be collected and measured on a daily basis to track the EBP patterns on patients in mechanical ventilation. Pre-clinical studies have shown that EBP can measure the extent of lung injury over time (onset of ARDS and recovery (unpublished data))

    Measurements are also planned for patients who are on mechanical ventilation on extracorporeal membrane oxygenation (ECMO) support as well.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    300 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Exhaled Breath Particles as a Clinical Indicator for Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) in Coronavirus (Covid-19) Positive and Negative Patients
    Actual Study Start Date :
    May 1, 2020
    Anticipated Primary Completion Date :
    May 1, 2024
    Anticipated Study Completion Date :
    May 1, 2025

    Arms and Interventions

    Arm Intervention/Treatment
    COVID-19 positive

    COVID-19-positive patients with pulmonary infection, ALI or ARDS

    COVID-19 negative

    COVID-19-negative patients with pulmonary infection, ALI or ARDS

    Outcome Measures

    Primary Outcome Measures

    1. Concentration of COVID-19 through PCR testing of EBPs [12-36 months]

      Real Time-PCR will be used to detect the presence of COVID-19 on membranes on which EBP have been collected to determine the efficacy of using the collection device for non-invasive detection of infection.

    2. Protein concentration in EBP [12-36 months]

      Proteins will be measured in the samples of EBPs collected on the membrane for the purpose of identifying protein biomarkers of disease.

    3. Particle flow rate (particles per minute) in exhaled air [12-36 months]

      The investigators have recently shown that Exhaled Breath Particles (EBP) measured as particle flow rate (PFR) from the airways could be used as a noninvasive real time early detection method for primary graft dysfunction (similar to ARDS) in lung transplant patients and for ARDS in a large animal model. PFR has been shown to increase before the cytokine storm which is a hallmark of ARDS. Early detection of ALI and ARDS is crucial for increasing a patient's chance of survival as it allows for early treatment, such as preparing for intensive care, prone positioning and protective mechanical ventilation settings. In the present study the investigators aim to use real-time PFR as an early detector for COVID-19-induced ARDS.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Clinical diagnosis of ALI

    • Clinical diagnosis of ARDS

    • COVID-19 infection as measured by a positive PCR test

    Exclusion Criteria:
    • Dementia

    • Severe neurological disease

    • Drug abuse

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Region Skåne Lund Skåne Län Sweden 22460

    Sponsors and Collaborators

    • Lund University Hospital

    Investigators

    • Principal Investigator: Sandra Lindstedt Ingemansson, MD, PhD, Region Skåne, Lund University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Lund University Hospital
    ClinicalTrials.gov Identifier:
    NCT04503057
    Other Study ID Numbers:
    • PEx ARDS
    First Posted:
    Aug 6, 2020
    Last Update Posted:
    Apr 12, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Lund University Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 12, 2022